Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.

BACKGROUND: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. MATERIAL AND METHODS: From January 2001 to September 2006 we treated with imatinib...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Breccia, Massimo, Girmenia, Corrado, Latagliata, Roberto, Loglisci, Giuseppina, Santopietro, Michelina, Federico, Vincenzo, Petrucci, Luigi, Serrao, Alessandra, Salaroli, Adriano, Alimena., Giuliana
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Università Cattolica del Sacro Cuore 2011
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3113277/
https://ncbi.nlm.nih.gov/pubmed/21713076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2011.021
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια